Oncogenesis Inc.

Description

• OncoGenesis is addressing the tremendous, unmet clinical need for easy-to-use and accurate screening of women for cervical cancer. The company offers a comprehensive solution ranging from optimal specimen collection to point-of-care diagnostic testing that will set a new standard of care for the diagnosis and treatment of cervical cancer worldwide. Our goal is to provide a solution that clinically outperforms existing screening technologies in a cost-effective format that can be run anywhere in the world including resource-limited regions of the world where the problem of cervical cancer is greatest. To accomplish this, OncoGenesis has developed an effective self-collection device that allows women to obtain their own cervical specimen in the privacy of their home. In addition, the company is developing the CerMark multiplex biomarker test that measures the critical cellular changes in a cervical tissue specimen. By measuring these markers, the test will be able to detect the presence of cervical cancer and precancerous high-grade lesions as well as the progression (staging), and aggressiveness of the disease. The CerMark test will be available first on a laboratory-based system and then on our own Point-of-Care device.
• 

  Headquarters:875 Walnut Street Suite 150, Cary, North Carolina, United States

  More
• 

  Phone Number:

• 

  Website: https://www.oncogenx.com

• 

  Employees:6

• 

  Revenue:$1 - 10M

• 

  Legal Name:Oncogenesis Inc.

• Oncogenesis Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 332994  |

  Show More